Weight loss drug Ozempic may now smash these FTSE 100 stocks

The new breed of weight loss treatments may be a big win for the pharmaceutical sector but other FTSE 100 stocks may rue the day.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Even major FTSE 100 stocks aren’t immune to Black Swan events and one of them could be heading their way in the shape of GLP-1 weight loss drugs like Ozempic and Wegovy.

These are the two best known prescription medications for people living with obesity. Their early success has put a rocket under the shares of Danish pharmaceutical company Novo Nordisk, now Europe’s biggest company. Other sectors won’t come out of this so well.

GLP-1 drugs were developed to treat type II diabetes, by helping users reduce blood sugar levels. They suppress appetite by telling the brain you’re full. They also slow digestion, so food takes longer to leave the body. It’s a huge step forward.

Unforeseen consequences

However, it may be a huge step backwards for FTSE 100 companies selling addictive products like sugar, alcohol and tobacco, which could experience a sharp drop in demand among their most avid users.

If I was the CEO of British American Tobacco, Imperial Brands and spirits maker Diageo, I’d be worried. We all know how hard it is to quit smoking. Around 30% of smokers try every year, but few succeed at the first attempt. 

Giving up drinking isn’t easy either. Dry January has made some inroads and younger drinkers are boozing less. There are an estimated 600,000 dependent drinkers in the UK, but less than one in five receive treatment. Now those who want to kick or cut back have another weapon in their armoury. Diageo’s biggest market is the US. Ozempic et al will be huge over there.

There could be a snowball effect too. As more people stop drinking, it will become easier for politicians to crack down on those who do. I’m keen to add Diageo to my portfolio, taking advantage of a 15% drop in its share price over the last year. Now there’s a new threat I hadn’t considered.

Could be a game changer

I did buy consumer goods giant Unilever recently, as its shares looked nicely priced. However, as well as soap and shampoo, Unilever owns Ben & Jerry’s, and we all know how addictive that is. Plus it owns Hellmann’s, Knorr, Magnum and Wall’s.

Associated British Foods could also be at risk. Its grocery brands include Allinson’s, Allied Bakeries, Blue Dragon, Patak’s, Kingsmill, Jordans, Mazola and Silver Spoon. ABF’s sugar business has the capacity to produce some 4.5m tonnes of sugar annually. Will the world be eating as much of it in future? At least ABF has Primark. All those newly slim shoppers will need a new wardrobe.

What about Tesco, Sainsbury’s, Ocado, Marks & Spencer Group? For that matter, what about The Restaurant Group? Greggs?

These are early days. Not everybody will be taking Ozempic. But with the Health Survey for England 2021 estimating 25.9% of adults in England are obese and a further 37.9% are overweight, many will be tempted. It’s something investors in FTSE 100 food, alcohol and tobacco stocks didn’t have to consider a few months ago.

Fortunately, there are plenty of other Footsie stocks that won’t be affected, whatever happens. There are plenty that I’m bullish on right now, too many to mention them all here of course. Make no mistake, I still believe buying shares in quality companies is the best route to wealth generation available to us all!

Harvey Jones has positions in Unilever Plc. The Motley Fool UK has recommended Associated British Foods Plc, British American Tobacco P.l.c., Diageo Plc, Imperial Brands Plc, J Sainsbury Plc, Novo Nordisk, Ocado Group Plc, Tesco Plc, and Unilever Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

What on earth’s going to happen to the BP share price in 2026?

Harvey Jones looks at how the BP share price is shaping up for the year ahead, and finds investors have…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Have a £20,000 lump sum? Here’s how to target a £8,667 yearly passive income

How to turn £20,000 into a £8,667 passive income? Our Foolish author explains one counterintuitive strategy to build such an…

Read more »

British coins and bank notes scattered on a surface
Dividend Shares

2 dividend stocks that yield double the current UK interest rate

Following the latest UK interest rate cut, Jon Smith points out a couple of options that offer generous income relative…

Read more »

Investing Articles

A 9% yield and now this! Check out the stunning Taylor Wimpey share price forecast for 2026

Harvey Jones has kept the faith in Taylor Wimpey shares despite a difficult run, bolstered by their incredible yield. Next…

Read more »

Investing Articles

How much do you need in an ISA to aim for a life-changing passive income of £30,000 a year?

Harvey Jones says ISA savers can transform their futures in 2026 by investing in FTSE 100 dividend stocks with huge…

Read more »

Investing Articles

My top 10 ISA and SIPP stocks in 2026

Find out why a FTSE 100 investment trust is now this writer's top holding across his Stocks and Shares ISA…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

£10,000 invested in Rolls-Royce shares 5 Christmases ago is now worth…

James Beard reflects on the post-pandemic Rolls-Royce share price rally and whether the group could become the UK’s most valuable…

Read more »

Investing Articles

Will Nvidia shares continue their epic run into 2026 and beyond?

Nvidia shares have an aura of invincibility as an AI boom continues to benefit the chipmaker. Can anything stop the…

Read more »